Nutex Health, Inc.
Nutex Health, Inc. (NUTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nutx · stock forecast · 2 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$235
Consensus
$235
+74.8% upside
Low
$235
Median: $235 · Last Close: $134.41
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $137.37 | ↑ 2.20% |
1-day model range: $135.9–$138.83. Peak: $138.83 (+2.20%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $144 | +7.3% |
| 2028 | $150 | +11.7% |
| 2029 | $153 | +14.2% |
| 2030 | $155 | +15.6% |
| 2031 | — | +16.3% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NUTX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-26 | Maxim Group | Maintains | Buy→Buy |
| 2025-07-10 | Benchmark | Maintains | Buy→Buy |
| 2025-05-20 | Maxim Group | Maintains | Buy→Buy |
| 2025-05-15 | Benchmark | Maintains | Buy→Buy |
| 2025-04-09 | Benchmark | Maintains | Buy→Buy |
| 2025-04-08 | Maxim Group | Maintains | Buy→Buy |
| 2025-02-13 | Maxim Group | Maintains | Buy→Buy |
| 2024-11-12 | Maxim Group | Maintains | Buy→Buy |
| 2024-11-12 | Benchmark | Maintains | Buy→Buy |
| 2024-08-21 | Benchmark | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Nutex Health, Inc. (NUTX) stock. Of the recent 16 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover NUTX.
Analyst Recommendation Trends
NUTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$276M
↓ 71.9% YoY
Revenue Next Year
$303M
↑ 10.0% YoY
EPS This Year
$-8.09
EPS Next Year
$-2.02
↓ 75.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast NUTX EPS of $-8.09 for the current fiscal year, based on estimates from 1 analysts. The NUTX revenue forecast is $276M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NUTX stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NUTX price target is $235.00 (+74.8% upside), with an analyst consensus of Buy.
The NUTX short-term stock prediction for tomorrow is $137.37 (+2.20%). The NUTX stock price prediction for 2027 estimates an average of $144. The NUTX stock prediction for 2030 projects a range of $137–$173.
Nutex Health, Inc. trades on NASDAQ under the ticker NUTX. The NUTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
NUTX forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month NUTX price target is $235.00, with a high forecast of $235.00 and a low of $235.00. The median price target is shown in the chart above when available. This implies +74.8% potential upside from the current price of $134.41.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.